Harrow Health logo
Harrow Health
HROW | NASDAQ
Chart Builder DCF Calculator
$29.09
-$1.03 (-3.42%)
At close: Nov 16, 2026, 4:00 PM ET
$29.00
-$0.09 (-0.31%)
After-hours: Nov 16, 2026, 7:30 PM ET

Harrow Health Company Profile

Company profile explained

Company Profile

Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.

Key Executives

Name Position
Francis W. Mullery President & Chief Executive Officer of Harrow's ImprimisRx Division
Mark L. Baum CEO, Chairman of the Board & Founder
Amir W. Shojaei Chief Scientific Officer
Andrew R. Boll President, CFO & Chief Accounting Officer
Brett A. Burrell Vice President of Legal & Compliance
Kim Barratt Chief Talent Officer
Mark A. Mannebach Head of Regulatory Affairs & Pharmacovigilance
Michael D. Biega Vice President of Investor Relations & Communications
Patrick W. Sullivan Chief Commercial Officer
Prashanth S. Annavajjhala Chief of Staff
Randall E. Pollard Chief Accounting Officer

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 05, 2026 8-K Current Report
Sep 04, 2026 8-K Current Report
Aug 17, 2026 4 Filing
Aug 10, 2026 10-Q Quarterly Report
Aug 10, 2026 8-K Current Report
Aug 06, 2026 8-K Current Report
Jul 31, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 22, 2026 4 Filing
Jun 22, 2026 4 Filing
View All SEC Filings ➞
Harrow Health
Harrow Health logo
Country United States
IPO Date Sep 28, 2007
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 373
CEO Mark L. Baum

Contact Details

1A Burton Hills Boulevard Nashville, Tennessee 37215 United States

Stock Details

Ticker Symbol HROW
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001360214
CUSIP Number 415858109
ISIN Number US4158581094
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.